INDV · Indivior Pharmaceuticals, Inc.
$40.52
+2.40% last session
End-of-day data · updated 2026-07-28
Market cap
$5B
Enterprise value
$5B
Trailing P/E
20.5
Forward P/E
9.6
Dividend yield
—
Beta
1.15
Avg volume
2M
Employees
1K
2D change
-1.22%
5D change
-1.18%
10D change
-1.26%
30D change
-4.30%
60D change
11.13%
MTD change
-0.55%
YTD change
11.57%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — INDV
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-18
Latest call per bank · past 12 months
Barclays
Overweight$46.00
+13.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-18 | Barclays | Initiates | Overweight | $0.00 → $46.00 |
| 2026-01-12 | HC Wainwright & Co. | Maintains | Buy | $35.00 → $48.00 |
| 2025-10-31 | Piper Sandler | Reiterates | Overweight | $27.00 → $41.00 |
| 2025-10-30 | HC Wainwright & Co. | Maintains | Buy | $28.00 → $35.00 |
| 2025-08-27 | Craig-Hallum | Maintains | Buy | $27.00 → $34.00 |
| 2025-08-06 | HC Wainwright & Co. | Initiates | Buy | $0.00 → $28.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 57 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 5.5% above the 50-day MA ($38.86).
- Price vs 200-day MA: Trading 20.0% above the 200-day MA ($34.15).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.12) — short-term momentum is fading.
- 52-week range: Price is within 5% of the 52-week high ($41.83).
INDV Price Chart
Loading chart for INDV…
Fundamentals
About Indivior Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$56B 11.9% YTD
HLN
Haleon plc
$44B -0.4% YTD
TEVA
Teva Pharmaceutical Industries
$36B -0.4% YTD
ZTS
Zoetis Inc.
$32B -37.9% YTD
UTHR
United Therapeutics Corporation
$26B 8.3% YTD
VTRS
Viatris Inc.
$21B 43.9% YTD
NBIX
Neurocrine Biosciences, Inc.
$18B 24.4% YTD
ELAN
Elanco Animal Health Incorporat
$13B 12.3% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.